Decoy Therapeutics Joins Webull Corporate Connect Service Platform

Core Viewpoint - Decoy Therapeutics, Inc. has joined the Webull Corporate Connect Service platform to enhance communication and transparency with its shareholders and investors [1]. Group 1: Company Overview - Decoy Therapeutics is a preclinical-stage biotechnology company focused on developing peptide conjugate therapeutics targeting serious unmet medical needs, particularly in respiratory viruses and gastrointestinal cancers [1]. - The company utilizes machine learning and artificial intelligence tools alongside high-speed synthesis techniques to design and manufacture drug candidates [1]. - Decoy has secured financing from institutional investors and non-dilutive capital sources, including the Massachusetts Life Sciences Seed Fund and the Google AI startup program [1]. Group 2: Webull Corporate Connect Service - The Webull Corporate Connect Service platform will allow Decoy to communicate corporate content such as news, earnings reports, and product updates directly to shareholders [1]. - The CEO of Decoy Therapeutics emphasized the importance of expanding awareness and engagement with the investor community as part of their strategic initiatives [1]. - Current Webull users can follow Decoy Therapeutics through the app to stay updated on the company's developments [1].